Genes Linking MS and Cancer: What Patients Should Know

Credibility

Interest

Key Takeaway

Some genetic differences linked to MS also affect risk for certain cancers — often in opposite directions — but having MS itself was not shown to cause cancer.

What They Found

Researchers looked at large genetic datasets for MS and 12 common cancers to see if genes that raise MS risk also change cancer risk.They found no proof that being genetically likely to get MS causes more or fewer cancers overall — that means MS itself wasn't shown to cause cancer in this study.However, at specific spots in the genome (locations of genes), they found 12 places where the same genetic region affects both MS and certain cancers.In many of those shared spots, the same genetic change raised the chance of MS but lowered the chance of cancer (this is called antagonistic pleiotropy — like a trade-off where a change helps in one way but hurts in another).One clear example was a change near the BACH2 gene: a tiny DNA change that seems to increase MS risk by lowering BACH2 activity, while at the same time it appears to reduce risk of some skin cancers.

Who Should Care and Why

People with MS and their caregivers should know that this research suggests some genes influence both immune problems and cancer risk, but MS itself was not shown to cause cancer — so having MS does not automatically mean a higher cancer risk based on this study.Clinicians and neurologists may use these findings to better understand biological links between the immune system and cancer; think of it like learning how one control dial in the body affects two different machines.Patients on immune-related treatments should still follow routine cancer screenings recommended by their doctors, because this study looks at inherited genes, not the effects of medications or infections.Researchers and drug developers could use the specific genes found (like BACH2) as clues to design treatments that try to help MS without increasing cancer risk — like aiming for a narrower target instead of a wide switch.Caregivers can use this information to reassure loved ones: genetics are complex and sometimes a change that raises one risk lowers another; overall, this work points to careful, personalized medical follow-up rather than alarm.

Important Considerations

This study looked at inherited genetic risk, not the effects of MS treatments, infections, or lifestyle — those can also change cancer risk and were not tested here.The shared genetic effects were found at specific gene locations and do not mean everyone with MS has different cancer risks; genetic effects can be small and vary between people.Because genetics is only one piece of the puzzle, patients should not change treatments or skip screenings based on this study alone — always discuss questions with a healthcare provider.

Categories:

MS Genetics Early Research MS Progression

Article Topics:

cancermendelian randomizationmultiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of clinical and translational neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News